FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
SpringWorks is in the air for Merck KGaA
The deal isn’t done, but would be Merck’s biggest oncology buy.
NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
